Merus (NASDAQ:MRUS) Sets New 1-Year High – Should You Buy?

Merus N.V. (NASDAQ:MRUS)’s share price hit a new 52-week high during trading on Thursday . The stock traded as high as $95.35 and last traded at $95.24, with a volume of 73210 shares changing hands. The stock had previously closed at $95.18.

Wall Street Analyst Weigh In

MRUS has been the subject of several recent research reports. UBS Group lowered Merus from a “buy” rating to a “neutral” rating and raised their price objective for the company from $72.00 to $97.00 in a research report on Tuesday, September 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Merus in a report on Wednesday, October 8th. Truist Financial downgraded Merus from a “buy” rating to a “hold” rating and raised their price target for the company from $88.00 to $97.00 in a report on Monday, September 29th. Barclays restated an “equal weight” rating and set a $97.00 price target (down from $112.00) on shares of Merus in a report on Tuesday, September 30th. Finally, Industrial Alliance Securities set a $90.00 price target on Merus in a report on Monday, August 25th. Four investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $92.35.

Merus Trading Down 0.0%

The firm has a fifty day moving average of $82.77 and a 200 day moving average of $64.66. The company has a market capitalization of $7.22 billion, a P/E ratio of -17.96 and a beta of 1.26.

Merus (NASDAQ:MRUS) last released its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($1.17) by ($1.06). Merus had a negative return on equity of 52.99% and a negative net margin of 673.31%.The business had revenue of $8.83 million during the quarter, compared to the consensus estimate of $9.77 million. Sell-side analysts anticipate that Merus N.V. will post -3.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Merus

Large investors have recently bought and sold shares of the business. Farther Finance Advisors LLC increased its holdings in Merus by 10,400.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock worth $49,000 after buying an additional 520 shares in the last quarter. CWM LLC increased its holdings in Merus by 299.0% in the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock worth $42,000 after buying an additional 601 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in Merus by 955.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company’s stock worth $76,000 after buying an additional 1,624 shares in the last quarter. Bessemer Group Inc. increased its holdings in Merus by 1,170.6% in the 3rd quarter. Bessemer Group Inc. now owns 2,160 shares of the biotechnology company’s stock worth $204,000 after buying an additional 1,990 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in Merus in the 3rd quarter worth about $207,000. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.